New blood thinning combo could cut ECMO bleeding and clotting risks

NCT ID NCT06676085

Recruiting now Disease control Sponsor: Beijing Chao Yang Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new way to manage blood thinning in patients on ECMO, a machine that helps the heart and lungs. The goal is to reduce bleeding and clotting problems, which affect over 40% of ECMO patients. Researchers will compare a combination of two blood thinners (nafamostat and heparin) against standard heparin alone in 140 adults with severe respiratory failure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nafamostat combined with unfractionated heparin
What this could lead to: If successful, this could lead to a safer way to manage blood thinning in ECMO patients, reducing dangerous bleeding and clotting events.
What could go wrong: This is an early-stage trial with only 140 participants, so results may not apply to all patients. The new method could still cause bleeding or clotting issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ECMO are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ECMO

Contacts and locations

Locations

Bing Sun
RECRUITING

Beijing, Beijing Municipality, 100020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.